Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Multi-Center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-Line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney

Next Previous
Search
Trial Profile

A Randomized, Open-Label, Multi-Center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-Line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Bevacizumab; Interferon alpha-2a
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms RECORD-2
  • Sponsors Novartis

    • Most Recent Events

    • 09 Aug 2017 This study has been discontinued in Belgium.
    • 01 May 2016 This trial was prematurely terminated in Czech Republic,Netherlands and in Hungary, Estonia, Italy (end date:2013-04-15) according to the European Clinical Trials Database.
    • 31 May 2013 Two-year overall survival and tolerability results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top